Study: Weight Loss Drugs Cut Risk of Four Cancers by Half or More

Health & LifestyleNews
175

Listen to article (english)

Translate to Spanish or other 102 languages!

Could GLP-1s help prevent cancer? A large study finds a link to reduced risk in several types of obesity-related cancers. Image for illustration purposes
Could GLP-1s help prevent cancer? A large study finds a link to reduced risk in several types of obesity-related cancers. Image for illustration purposes

Medical News Today

- Advertisement -

The use of glucagon-like peptide-1 (GLP-1) receptor agonistTrusted Source medications continues to rise, with a 155% increaseTrusted Source in the percentage of people with type 2 diabetes taking these drugs from 2018 to 2022. 

The use of GLP-1s for weight loss is also increasing. The latest polls report that of the one in eight Americans who have taken a GLP-1 medication, about 38% have only taken them to help lose weight.

Follow the link below to Medical News TOdy to read the full story:

- Advertisement -

https://www.medicalnewstoday.com/articles/weight-loss-drugs-glp-1-slash-risk-4-types-cancer-50-or-more-study?utm_term=feature&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2026-06-17&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Summer Readiness: Keep Your Family Safe with These Heat Tips
Next article
STHS Behavioral to Host Webinar on Minority Mental Health, July 2nd

More Articles

DHR Health Expands Kidney Transplant Program with Transplant Nephrologist, Dr. Victor E. Prado

As part of its ongoing commitment to bringing world-class healthcare to the Rio Grande Valley, DHR Health is pleased to announce the addition of double board-certified transplant nephrologist, Dr. Victor E. Prado. Dr. Prado will provide care to patients at DHR Health’s Transplant Institute,

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.

HHS Opens $1 Million Funding Opportunity to Strengthen Women’s Preventive Care

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced a Notice of Funding Opportunity (NOFO) for the Women’s Initiative for Screening and Health (WISH) program.
- Advertisement -